FOCL · Edap TMS
AI read · Neutral
The AI's read
Focal Therax reported 39% YoY HIFU revenue growth to $13.2M, 55.6% gross margin, and completed a $40M equity raise to fund expansion. Management guided $50–54M for 2026 and cited more Focal One installs and margin leverage. The market sold off; FOCL is down ~3.8% and RSI ~26.8, so the stock looks oversold even after the beat. The decline suggests investors are fretting about dilution or execution despite the operational improvement. Our take is MIXED. Fundamentals improved and cash reduces runway risk, but the equity raise and the price action muddy near-term upside, so we want confirmation on procedure growth and install cadence before leaning bullish.